Clinical Trials in Michigan

Showing 9461-9480 of 16,154 trials

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

NCT02476955

An Open-label Phase 1b Study of ARQ 092 in Combination with other Antineoplastic Agents in Subjects with Selected Solid Tumors

Solid TumorsOvarian CancerEndometrial Cancer

ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA)41 participantsStarted Jun 2015

Grand Rapids, Michigan, United States • New York, New York, United States • Oklahoma City, Oklahoma, United States +2 more locations

COMPLETEDPhase 262 miles

A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema

NCT02699450

This is a multiple-center, multiple-dose, randomized, active comparator-controlled, double-masked, three parallel group, 36-week study in participants with center-involving diabetic macular edema (DME). Only one eye will be selected as the study eye. Where both eyes meet all eligibility criteria, the eye with the worse best corrected visual acuity (BCVA) will be defined as the study eye. The study will consist of a treatment period (20 weeks) and an observational period (up to 16 weeks). Treatment naive participants will be randomized in a 1:1:1 ratio to one of the Arms A, B and C, respectively. Participants previously treated with intravitreal (IVT) anti-vascular endothelial growth factor (VEGF) will be randomized in a 1:1 ratio to Arms A and C.

Diabetic Macular Edema

Hoffmann-La Roche229 participantsStarted Apr 2016

Phoenix, Arizona, United States • Phoenix, Arizona, United States • Phoenix, Arizona, United States +57 more locations

Open-label Phase 1b Study of ARQ 092 in Combination With Anastrozole

A Study of Faricimab (RO6867461) in Participants With Center-Involving Diabetic Macular Edema

Find Trials by Condition in Michigan

EVOLVE Short DAPT Study

A Study to Assess Resistance and Durability of Response to ABT-493 and/or ABT-530

Evaluation of Exufiber Ag+ and Other Gelling Fibre Dressings

Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis

A Study of Tucatinib (ONT-380) Combined With Ado-trastuzumab Emtansine (T-DM1) in Patients With HER2+ Breast Cancer

Study of Rhopressa® for the Reduction of Elevated Intraocular Pressure in Patients With Glaucoma or Ocular Hypertension in a Real-world Setting

Spinal Cord Injury Registry - North American Clinical Trials Network

Multi-Center Study of Iron Overload: Survey Study (MCSIO)

A Study of GDC-0853 in Participants With Refractory Chronic Spontaneous Urticaria (CSU).

Musculoskeletal Impairment in Headaches Attributed to Rhinosinusitis

Study Evaluating ERB-041 With Methotrexate in Rheumatoid Arthritis

A Multi-Center Study of Ibrutinib in Combination With Obinutuzumab Versus Chlorambucil in Combination With Obinutuzumab in Patients With Treatment naïve Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Ph 1 Study in Subjects With Tumors Requiring Arginine to Assess ADI-PEG 20 With Pemetrexed and Cisplatin

A Study to Evaluate the Pharmacodynamic Activity of E2082 in Adult Participants With Photosensitive Epilepsy

A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene

Pacritinib Versus Best Available Therapy to Treat Myelofibrosis

Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

A Treatment-Option Protocol to Provide Brentuximab Vedotin to Eligible Patients Completing Studies SGN35-005 or C25001